scholarly journals Outbreak of mumps associated with poor vaccine efficacy - Oporto Portugal 1996

1998 ◽  
Vol 3 (12) ◽  
pp. 119-21 ◽  
Author(s):  
G Gonçalves ◽  
A de Araújo ◽  
M. L. Monteiro Cardoso

Vaccination against mumps in Portugal began in 1987, with the introduction of the combined measles, mumps, and rubella vaccine (MMR) in the national vaccination programme (Programa Nacional de Vacinação: PNV) for both sexes at 15 months. In November 1990,

2002 ◽  
Vol 6 (5) ◽  
Author(s):  
H Houweling

The Gezondheidsraad (Health Council) in the Netherlands was asked to advise the minister of health on the revision and possible expansion of the national vaccination programme, and consequently published a recommendation on universal vaccination against infections with group C meningococci and pneumococci recently.


2001 ◽  
Vol 5 (51) ◽  
Author(s):  
G Gonçalves ◽  
M. A. Santos ◽  
S Afonso ◽  
R Jorge ◽  
C D Pinheiro ◽  
...  

The recommendations for adult immunisation in Portugal’s Programa Nacional de Vacinação (PNV, national vaccination programme) (1) include the following.


2018 ◽  
Vol 48 (1) ◽  
pp. 96-105 ◽  
Author(s):  
Kenneth B. Pedersen ◽  
Marie E. Holck ◽  
Aksel K.G. Jensen ◽  
Camilla H. Suppli ◽  
Christine S. Benn ◽  
...  

Aims: Delay of childhood vaccinations is common and influences efforts to reduce targeted diseases. In Denmark, the diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b (DTaP-IPV-Hib) vaccine is recommended at ages 3, 5 and 12 months and the first measles–mumps–rubella vaccine (MMR-1) at 15 months. Following guidelines, children delayed at age 15 months should receive MMR-1 and DTaP-IPV-Hib-3 simultaneously, unless DTaP-IPV-Hib-2 was received less than 6 months ago, when MMR-1 alone is recommended. We studied compliance with these guidelines and the reasons for non-compliance with a focus on vaccination providers. Methods: We used a nationwide register-based cohort study of children born in Denmark between January 2000 and June 2013, who were lacking MMR-1 and DTaP-IPV-Hib-3 at age 15 months and were followed to 24 months. We also performed semi-structured telephone interviews with vaccination providers. Results: The study consisted of 156,921 children (18% of the children born in the period). Among the 40,060 children who had received DTaP-IPV-Hib-2 less than 6 months ago, 37,892 (95%) received MMR-1 alone. Among the 88,469 children who had received DTaP-IPV-Hib-2 more than 6 months ago, 6334 (7%) received DTaP-IPV-Hib-3 and MMR-1 simultaneously. The interviews indicated that some vaccination providers are reluctant to give multiple vaccinations at the same visit and some have a preference of following the usual sequence in the programme. Conclusions: Vaccination providers generally complied with the recommended minimum 6 months’ interval between DTaP-IPV-Hib-2 and DTaP-IPV-Hib-3. Conversely, there was a low compliance with the recommendation to administer DTaP-IPV-Hib-3 and MMR-1 simultaneously. More efforts are needed to ensure timely vaccination.


2004 ◽  
Vol 132 (4) ◽  
pp. 685-692 ◽  
Author(s):  
G. CILLA ◽  
M. DORRONSORO ◽  
J. R. SÁENZ-DOMÍNGUEZ ◽  
E. SERRANO ◽  
E. PÉREZ-TRALLERO

In Spain, vaccination against rubella was initiated in schoolgirls in the mid-1970s. In Gipuzkoa, subsequent extensions to the vaccination schedule culminated in 1992 with the introduction of the two-dose measles, mumps and rubella vaccine in children and adolescents of both sexes. Moreover, in 1985 a programme for the identification and vaccination of non-immune parturient women was implemented in the region's main hospital. The prevalence of rubella-susceptible parturient women decreased from 3·7% at the beginning of the study to <1·5% by 1992. Despite this overall decrease, 4·8% of adolescent parturients were susceptible to rubella during 2001–2002. From 1984, the number of reported cases of rubella (children and adults) progressively decreased until 1997, after which there have been no cases of indigenous rubella. There have been no cases of reported congenital rubella since 1984. These results indicate that the vaccine policy carried out in this geographical area has been effective in achieving considerable progress towards rubella elimination.


2002 ◽  
Vol 6 (12) ◽  
Author(s):  
Ø Løvoll ◽  
S Sandbu

The Gezondheidsraad (Health Council) in the Netherlands was asked to advise the minister of health on the revision and possible expansion of the national vaccination programme, and consequently published a recommendation on universal vaccination against infections with group C meningococci and pneumococci recently (1).


Sign in / Sign up

Export Citation Format

Share Document